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Open access under CC BYA hierarchical in silico screening procedure using the crystal structure of an agonist bound chimeric a7/
Ls-AChBP protein was successfully applied to both proprietary and commercial databases containing
drug-like molecules. An overall hit rate of 26% (pKi 5.0) was obtained, with an even better hit rate of
35% for the commercial compound collection. Structurally novel and diverse ligands were identiﬁed.
Binding studies with [3H]epibatidine on chimeric a7/5-HT3 receptors yielded submicromolar inhibition
constants for identiﬁed hits. Compared to a previous screening procedure that utilized the wild type
Ls-AChBP crystal structure, the current study shows that the recently obtained a7/Ls-AChBP chimeric
protein crystal structure is a better template for the identiﬁcation of novel a7 receptor ligands.
 2012 Elsevier Ltd. Open access under CC BY license.1. Introduction
Nicotinic acetylcholine receptors (nAChRs) are members of the
Cys-loop family of ligand-gated ion channels (LGICs).1–3 This fam-
ily also includes receptors for serotonin (5-HT3R), c-aminobutyric
acid (GABAAR) and glycine (GlyR).1–3 The Cys-loop receptors all
share a common architecture of ﬁve subunits that combine to form
an agonist-responsive receptor with an integral ion channel (with
approximately ﬁvefold symmetry) that spans the cell membrane.
Within each receptor type there are several subunits and different
combinations of these subunits form receptor subtypes with differ-
ent pharmacological characteristics.1–4 The human nAChR subunits
include a1–a7, a9, a10, b1–b4, d, e and c subunits. In principle,
there are many possible combinations, but two nAChR subtypes
are most commonly seen in the central nervous system (CNS),
namely a4b2 and a7 receptors.5 These are mainly found on neuro-
nal cells in the CNS where they are considered to be important
drug targets in CNS disorders such as Alzheimer’s disease, Parkin-
son’s disease, schizophrenia and some forms of epilepsy.1–4 These
nAChRs are also involved in the physiology of anxiety, memory,: +31 20 5987610.
 license.cognition, pain and addiction.1–4 The human a7 receptor is also
found on non-excitable cells in the periphery where it is believed
to be a pharmacological target for inﬂammation and some forms
of cancer.6,7
Insight into the structure of the nicotinic receptor ligand-bind-
ing domain (LBD) has been derived from high resolution crystal
structures of acetylcholine-binding proteins (AChBPs).8–11 AChBPs
have been recognized as water-soluble homologs of the LBD of
LGICs and have been obtained from different snail species such
as Lymnaea stagnalis (Ls-AChBP),8,9 Aplysia californica (Ac-AChBP)11
and Bulinus truncatus (Bt-AChBP).10 AChBPs show similarity in se-
quence identity (20–24% between AChBPs and nAChRs) and
structure (similar size and architecture, pentameric assembly) to
the LBD of nicotinic receptors.8–11 In particular, aromatic residues
that form the binding pocket are conserved between AChBPs and
nAChRs, and AChBPs bind several reference nicotinic receptor li-
gands such as nicotine, epibatidine and lobeline. As AChBPs are
extracellular and water soluble proteins that can be obtained in
relatively high yields, several have been crystallized in complex
with selective and high afﬁnity nicotinic receptor ligands, for
example, Ls-AChBP in complex with nicotine and Ac-AChBP in
complex with epibatidine.11,12 The availability of these AChBP crys-
tal structures has signiﬁcantly improved our understanding on the
overall molecular structure of the nicotinic receptor LBD and its
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Figure 1. RMSD values per residue (a7/Ls-AChBP chimera numbering) for the principal (A) and complementary (B) subunits. The binding pocket residues Y91 (loop A), W145
(loop B) and Y184–Y192 (loop C) of the principal side and residues W53 (loop D) and L104–L116 (loop E) of the complementary side all have RMSD values lower than 2 Å.
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its moderate overall sequence identity (24% with the human a7
receptor LBD), AChBP cannot be considered an exact water-soluble
mimic of the nicotinic receptor LBD. Recent work has shown that
structure–activity relationships (SAR) that were identiﬁed for ACh-
BP do not always correlate with SAR for a7 or the a4b2 nAC-
hRs.13,14 Deviation in amino acid composition between AChBP
and nicotinic receptors, particularly in the complementary face of
the binding site, are likely causes for the observed SAR differences.
Despite these structural differences, AChBP crystal structures
have been successfully used in in silico (virtual) screening proce-
dures by our research group15,16 and others,17,18 and novel ligands
with afﬁnity for AChBPs and nAChRs have been obtained. In our
ﬁrst in silico screen, we used crystal structures of Ls-AChBP in com-
plex with nicotine (PDB: 1UW6), HEPES (PDB: 1UX2) and car-
bamylcholine (PDB: 1UV2).15 Using identical protocols and
screening libraries, the crystal structures in complex with nicotine
and HEPES performed considerably better in the identiﬁcation of
novel AChBP and a7 receptor ligands, compared to the Ls-AChBP
crystal structure in complex with carbamylcholine. These ﬁndings
show that small structural differences between crystal structuresof a speciﬁc protein can have profound effects on the outcome of
in silico screening campaigns.
A recently reﬁned in silico screening procedure (using the Ls-
AChBP crystal structure in complex with nicotine) was able to
identify novel and diverse scaffolds for the target protein AChBP,16
but it was less successful in identifying ligands for its therapeuti-
cally relevant structural homolog, the a7 nicotinic receptor. This
clearly indicates some of the limitations of using AChBP as a tem-
plate for ﬁnding nicotinic receptor ligands.
Very recently, a crystal structure of a chimeric a7/Ls-AChBP
protein in complex with the agonist epibatidine has been obtained
by Li and co-workers.19 This protein shares 64% sequence identity
with the human a7 extracellular LBD and residues lining the bind-
ing pocket are completely derived from the a7 receptor. Having de-
tailed structural information of the binding pocket of a very close
homolog to the human a7 receptor, we applied our in silico screen-
ing procedure on this agonist-bound crystal structure with the aim
of identifying novel chemotypes for the a7 nicotinic receptor.
Our hierarchical in silico screening procedure was successfully
applied on a commercial compound collection to identify novel
a7 receptor ligands with a good hit rate of 35%. As such, our efforts
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Figure 2. Structural comparison between Ls-AChBP (blue) and the a7/Ls-AChBP chimeric protein (green). (A) In general, the backbone fold between the two proteins is
similar, especially close to the binding pocket, which is located within the circle (red dashed circle). (B) The residues aligning the binding pocket in general superpose well.
However, there are differences in amino acid composition and loop conformation. (C) For the principal side, the aromatic residues are conserved and loop C has a similar fold
in both proteins with only minor differences in the tip of loop C. (D) The residues of the complementary side are not conserved between both proteins, with the exception of
W53 (both Ls-AChBP and a7/Ls-AChBP numbering) and L102 (Ls-AChBP numbering). However, differences in the side chain orientation exist for W53. Carbon atoms of Ls-
AChBP and the a7/Ls-AChBP chimeric protein are depicted in blue and green, respectively. Ligand carbon atoms are depicted in grey for nicotine and black for epibatidine. The
bridging water molecule of the nicotine-bound Ls-AChBP structure is depicted in red. L102 and L104 are shown in C and D for clarity. Residue numbering is depicted as ‘Ls-
AChBP residue number’/‘chimeric protein residue number’.
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ical starting points that can be used for further optimization to-
wards novel high afﬁnity a7 nicotinic receptor ligands. When
comparing to our previous Ls-AChBP-based in silico screening
exercise, the current study shows that the recently obtained a7/
Ls-AChBP chimeric protein crystal structure is a better template
for identiﬁcation of novel a7 receptor ligands than the previously
used Ls-AChBP crystal structure.
2. Results
2.1. Comparing the binding pockets of the chimeric a7/Ls-
AChBP protein and Ls-AChBP protein
We compared the subunits A and B of both the chimeric a7/Ls-
AChBP protein (PDB: 3SQ6; residues lining the binding pocket arecompletely derived from the a7 receptor) and Ls-AChBP (PDB:
1UW6), by means of a structural superposition using their Ca-
atoms. The Ca-atoms of both proteins superpose well (principal
face: RMSD = 1.7 Å for 204 residues; complementary face:
RMSD = 1.8 Å for 204 residues) and the RMSD per residue (Ca-
atoms) of the principal and complementary sides are depicted in
Figure 1A and B, respectively. Most of the residues have low RMSD
values (1 Å), but several RMSD values are above 2 Å. These resi-
dues with higher RMSD values for their Ca-atoms (especially
RMSD2 Å), indicating a difference in the position of the backbone
atoms, are all located outside the binding pocket (Figs. 1A, B and
2A). Nevertheless, the superposition also reveals considerable dif-
ferences in residue composition and side chain orientation be-
tween the binding sites of both proteins (e.g., W53 and the tip of
loop C; Fig. 2B–D). As a result, some notable differences in possible
ligand–protein interactions between the two structures can be
Figure 3. Schematic representation of our hierarchical in silico screening procedure
using the crystal structure of the a7/Ls-AChBP chimeric protein (PDB: 3SQ6). (a)
generation of 3D coordinates, protonation; (b) selection of compounds with cationic
centers, conformation generation; (c) pocket volume, cationic center near W145;
(d) generation of stereoisomers, docking; (e) ranking, cation–p interactions; (f)
favorable poses, novel chemical structures; (g) binding assays; (h) proprietary
database; (i) world diversity set; (j) compounds with at least pKi 5. lig: ligands; st.
isom.: stereoisomers.
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substantially more polar Q114 in the chimeric a7/Ls-AChBP pro-
tein and may provide an opportunity to obtain speciﬁc polar inter-
actions with the a7 binding site. The speciﬁc rotameric
conﬁguration of W53 in the chimeric a7/Ls-AChBP enables another
possibility for formation of polar interactions with the binding site.
In contrast to the wild type Ls-AChBP structure, W53’s indole
nitrogen atom is pointing towards the binding site and therefore
provides ligands with an opportunity for hydrogen bond forma-
tion. It is noted that epibatidine is not involved in polar interac-
tions both with Q114 or the indole nitrogen of W53 in the
chimeric a7/Ls-AChBP protein structure.
2.2. Hierarchical in silico screening on proprietary and
commercial compound collection
We have previously successfully applied a hierarchical in silico
screening procedure, using a nicotine-bound Ls-AChBP cocrystal
structure, to both a proprietary and commercial compound collec-
tion. In the current project, we developed and applied a similar in
silico screening procedure using the cocrystal structure of the hu-
man a7/Ls-AChBP chimeric protein in complex with the agonist
epibatidine. The procedure consists of several ligand selection
steps with increasing complexity: (1) pre-selection of ligands con-
taining cationic centers (quaternary or protonated nitrogen atoms),
(2) a protein-based pharmacophore ﬁlter that selects ligands with
the appropriate size, shape and location of the essential cationic
center, (3) docking studies using the human a7/Ls-AChBP chimeric
protein crystal structure, and (4) post-processing of docking poses
(Fig. 3).
For comparison, we have used the same proprietary compound
collection (a diverse subset of 5315 drug-like compounds) as in our
previous study.16 All compounds with a cationic center were se-
lected (2059 compounds) and subjected to a conformation genera-
tion procedure prior to a pharmacophore screening. Subsequently,
1858 compounds were selected using the pharmacophore screen-
ing step. Since the GOLD docking program does not generate ster-
eoisomers during the docking procedure, a total of 3203
stereoisomers was generated (approximately 1.7 stereoisomers
per compound) using the ‘chiral_enumeration’ tool available for
the MOE software package (CCG, Montreal).
These 3203 compounds were docked into the binding pocket of
the chimeric a7/Ls-AChBP protein (PDB: 3SQ6) using the GOLD
Suite software package (v5.1, CCDC, Cambridge, UK). In order to se-
lect poses that are involved in cation–p interactions, deemed
essential for binding, the distances between the CD2 atoms of
W145 and the nitrogen atoms of the docked compounds were
determined. All poses for which this distance was larger than
5.5 Å were discarded. In addition, all poses in which parts of the
compounds are positioned outside the binding pocket and/or the
compounds show intra- or intermolecular steric clashes were also
discarded. The top-ranked 400 poses of the remaining compounds
were visually inspected for steric complementarity between com-
pound and binding pocket and for the occurrence of cation–p
interactions. In addition, when evaluating the binding poses, the
formation of hydrogen bonds (with the backbone carbonyl group
of W14520 and/or with the side chain hydroxyl group of Y91)
was preferred but not considered a strict requirement. Other pos-
sible hydrogen bonds between protein and compound were also
considered, such as interactions with W53 and Q114 (see Section
2.1). Finally, a diverse subset of 15 structurally new compounds
(compounds 1–15), which were not previously tested for a7 recep-
tor activity, was selected for binding assays on a chimeric a7/5-HT3
receptor (Figs. 4 and 5).21
Next, the World Diversity Set of Specs (WDS, obtained October
2011 from www.specs.net) was used as the commercial library.This database contains 19,455 chemically diverse compounds of
which 2324 compounds contained a cationic center (quaternary
or basic nitrogen atom). Similar as to the proprietary database
(Fig. 3), 1963 compounds were selected using a pharmacophore
screening step and 3516 stereoisomers were generated (approxi-
mately 1.8 stereoisomers per compound). These 3516 stereoiso-
mers were docked into the chimeric a7/Ls-AChBP protein (PDB:
3SQ6) and after the post-processing step, the best-ranked 350
poses were visually inspected to yield a subset of 23 structurally
new and diverse compounds for binding assays on the human a7
receptor (Figs. 4 and 6). As 4 of the 23 compounds were not avail-
able, close analogs were obtained to yield 23 compounds in total
(compounds 16–38).
2.3. Binding analysis on a chimeric a7/5-HT3A receptor
All 38 selected compounds (compounds 1–38), together with
the endogenous ligand acetylcholine, were tested in [3H]epibati-
dine competition studies on a chimeric a7/5-HT3A receptor.21 This
chimeric receptor was used as it contains the extracellular N-ter-
minal ligand binding domain of the human a7 receptor, binds a7
receptor ligands with a comparable afﬁnity as the wild type a7
receptor and is known to express well in HEK293 cells.21
The binding data of the 38 compounds from the proprietary and
commercial compound collection, epibatidine and the endogenous
ligand acetylcholine are depicted in Figure 4. We identiﬁed 10
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Figure 4. The binding afﬁnities (pKi) for the 38 selected ligands, epibatidine (pKd) and acetylcholine have been determined from 10-point competition curves with
[3H]epibatidine. Representative competition curves are shown for the 2 most potent ligands, compound 4 (pKi = 6.4 ± 0.2, n = 3) and compound 29 (pKi = 6.7 ± 0.2, n = 4). In
the bar graph above, compounds that showed binding with 10-point curves are shown as the mean ± S.E.M., n 3. Note that measurements of epibatidine afﬁnity were made
using the [3H]-radioligand and are therefore a pKd. Note that the values for compounds with low potencies (pKi <5) could be unreliable.
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together with the afﬁnity of epibatidine and acetylcholine, in
Table 1. Of the 10 hits, 2 compounds have similar or higher binding
afﬁnities than the endogenous ligand acetylcholine (compound 4:
pKi = 6.4 ± 0.2; compound 29: pKi = 6.7 ± 0.2; acetylcholine:
pKi = 6.3 ± 0.3; Fig. 4 and Table 1).
2.4. Structural novelty
To investigate if the validated hits contain novel chemotypes for
the a7 nAChR, a 2D topological similarity search (ECFP-4)22 has
been performed against known a7 receptor ligands. This set con-
sisted of 218 ligands in total and included well-known nicotinic
receptor ligands (e.g., epibatidine, nicotine, acetylcholine, cytisine,
PNU282987 and ARR-17779) supplemented with a7 receptor li-
gands from the ChEMBL database23 (molecular weight below 500
and Ki or EC50 10 lM). The results from this analysis are depicted
in Table 1 and indicate that only one of the identiﬁed hit com-
pounds (compound 29) is chemically similar to any known a7
nAChR ligand (ECFP-4 Tanimoto similarity 0.40,24 Table 1).
2.5. Binding modes of compounds 4 and 29
Our hierarchical in silico screening procedure resulted in two
hit compounds that show higher binding afﬁnity than acetylcho-
line on the chimeric a7/5-HT3A receptor (compounds 4 and 29,
see Table 1). Here we present the binding poses of these two com-
pounds which fulﬁll our criteria of ligand selection (i.e., (1) steric
complementarity between pocket and ligand, (2) presence of cat-
ion–p interactions, and (3) preferably occurrence of hydrogen
bonds).
Two binding poses have been obtained for compound 4 in com-
plex with the chimeric a7/Ls-AChBP protein crystal structure
(Fig. 7A and B). The binding pose with the highest score (Chem-
Score value = 36.5449; acetylcholine ChemScore value = 19.1944;epibatidine ChemScore value = 37.5699; Fig. 7A and B) forms cat-
ion–p interactions with W145 as the cationic nitrogen atom of
the ligand is at 5.4 Å distance from the aromatic side chain of
W145 (atom CD2). The protonated cationic nitrogen atom is also
involved in hydrogen bond formation with the carbonyl backbone
of W145. Interestingly, the ligand has taken an opposite binding
pose compared to epibatidine; its aromatic moiety is involved in
hydrophobic contacts with the residues of the aromatic cavity
within the binding pocket (W53, Y91, W145, Y184, Y191) and
the basic bicyclic moiety takes a similar position as the chloropy-
ridinyl ring of epibatidine. Hydrophobic contacts are also formed
with C186 and C187 of Loop C and L106 and L116 of the comple-
mentary side.
The second binding pose of compound 4 has a lower score
(ChemScore value = 34.6305; Fig. 7C and D). The cationic nitrogen
atom of the ligand is located closer to the aromatic plane of W145
compared to pose 1, which could result in a stronger cation–p
interaction with W145 (distance to atom CD2 of W145 = 4.9 Å).
In this pose, compound 4 is also involved in extensive hydrophobic
contacts with the binding site. However, compared to the ﬁrst
pose, the aromatic moiety of the ligand is not located in the aro-
matic cavity of the binding pocket and therefore not involved in
p–p interactions. On the other hand, this binding pose is more sim-
ilar to the binding mode of epibatidine as the aromatic and bicyclic
basic parts of 4 have taken similar positions in the binding site.
Furthermore, no formation of hydrogen bonds between the ligand
and protein binding site is observed. It is noted that in a recent
study by Srivastava et al. in which photolabeling of the human
a4b2 nAChR with azidoepibatidine was combined with docking
experiments in a a4b2 homology model, evidence for two distinct
binding orientations of epibatine was obtained.25 Interestingly, the
proposed binding poses of epibatidine resemble the two docking
poses that we obtained for compound 4. In the ‘up orientation’,
epibatidine’s basic nitrogen atom is accommodated by the
aromatic cavity whereas in the ‘down orientation’ the aromatic
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Figure 5. The chemical structures of the 15 ligands selected from our proprietary compound collection.
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chains. In addition, Brams et al. have shown by X-ray co-crystal
structures that strychnine and d-tubucurarine adopt to different li-
gand orientations in the binding site of Ac-AChBP, as well.26
For compound 29, only one binding pose was obtained that ful-
ﬁlled our selection criteria (ChemScore value = 35.2580; Fig. 7E
and F). The phenyl moiety of the ligands points towards the com-
plementary side of the binding pocket and occupies approximately
the same region as the chloropyridinyl ring of epibatidine. The cat-
ionic nitrogen atom of the ligand is buried into the aromatic cavity
of the binding pocket and is close enough to W145, Y184 and Y191
to enable cation–p interactions (distances 4.9 Å, 4.7 Å and 4.6 Å,
respectively). Hydrogen bonding between the cationic nitrogen
atom of the ligand and the binding pocket residues are not ob-
served in this docked pose.
3. Discussion and conclusions
In the current study, we have successfully applied our hierarchi-
cal in silico screening procedure on a novel crystal structure of achimeric a7/Ls-AChBP protein. The multi-step screening protocol
was applied on a proprietary compound collection and a diverse
commercial compound collection. Our efforts have resulted in
the identiﬁcation of 10 structurally novel ligands with binding
afﬁnity for the human a7 nicotinic receptor (pKi 5) and an overall
hit rate of 26% was obtained (10 of 38 compounds). For the screen-
ing of the commercial compound collection an even higher hit rate
of 35% (8 of 23 compounds) was observed. Two hit compounds
exhibited submicromolar binding afﬁnities (compound 4:
pKi = 6.4 ± 0.1 and compound 29: pKi = 6.7 ± 0.2).
In our previous hierarchical in silico screening procedure, the
crystal structure of Ls-AChBP in complex with nicotine was used
and a similar procedure was applied to the same two databases
as used here.16 In the previous study, a total of 35 compounds were
selected and the binding afﬁnity for both Ls-AChBP and the human
a7 receptor was determined. Of the tested compounds, 24 had an
afﬁnity (pKi) of at least 5.0 for Ls-AChBP (69%) including 12 with
pKi 6 (34%). However, for the human a7 receptor, a consider-
able lower hit rate was observed as only 2 compounds were iden-
tiﬁed with pKi 5 (5.0 ± 0.1 and 5.4 ± 0.1; 6%).16 In the current
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higher homology with the actual human a7 receptor (i.e., the a7/
Ls-AChBP chimeric protein) serves as a better structural template
for identifying novel a7 ligands. In addition, the afﬁnities of the
hits identiﬁed with the a7/Ls-AChBP chimeric protein crystal
structure are higher compared to the previous hits obtained with
the Ls-AChBP crystal structure (pKi: 5.0–6.7 vs pKi: 5.0–5.4). Thestructural differences in residue composition and side chain orien-
tation between the binding sites that are apparent when superpos-
ing both proteins (e.g., W53 and the tip of loop C, see superposition
in Fig. 2B and D) are likely causes for the observed difference in hit
rates on the a7 nicotinic receptor. For example, analyzing the
docking poses of the two highest afﬁnity hit compounds 4
and 29 in the structural superposition of the epibatidine-bound
Table 1
a7/5-HT3A receptor binding afﬁnities (pKi) of validated hit compounds (pKi 5) selected by a hierarchical in silico screening protocol (Fig. 3) against the chimeric a7/Ls-AChBP
protein crystal structure
Compd Structurea pKi a7/5-HT3Ab,c GOLDd (rank) ECFP-4e Closest known nAChR ligandf ChEMBLdb ID code
ACh 6.3 ± 0.4 — — — —
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Table 1 (continued)
Compd Structurea pKi a7/5-HT3Ab,c GOLDd (rank) ECFP-4e Closest known nAChR ligandf ChEMBLdb ID code
37
N+
OH
O
5.6 ± 0.2 30.0353 (300/350) 0.13
O
N+
1739327
GOLD docking scores (ChemScore) and the closest structural similarity to reference nicotinic receptor ligands are given for each validated hit based on ECFP-4 2D similarity
searches.
a The exact stereochemical composition of the samples tested is not known.
b pKi values are calculated from at least three independent measurements as the mean ± S.E.M.
c Measured by displacement of [3H]epibatidine binding using membranes of HEK293 cells transiently expressing an a7/5-HT3A chimeric receptor.
d Compounds BS7122 and BS7128 were selected from the top-ranked 400 compounds from the proprietary database. The other compounds have been selected from the
top-ranked 350 compounds from WDS.
e ECFP-4 circular ﬁngerprint Tanimoto similarity to closest known nAChR ligands in the ChEMBL database. A similarity higher than 0.40 is considered signiﬁcant.25
f Chemical structure of the nicotinic receptor ligand in the ChEMBL database with the highest structural similarity to the validated hit compound.
g Please note that measurements of epibatidine afﬁnity were made using the [3H]-radioligand and are therefore a pKd.
h These compounds have not been selected with the in silico screening, but are the closest available analogs from WDS. ACh: acetylcholine; Epi: epibatidine.
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(Section 2.1) suggests that tight hydrophobic interactions with
W53 and L116 (W53 and M114 in Ls-AChBP, respectively) are
the most likely determinants for identifying them as hits in the
current, but not in the previous study (Supplementary data
Fig. 1). Interestingly, in our previous Ls-AChBP-based work, very
close analogs of compound 4 were identiﬁed as Ls-AChBP hits
but not as a7 nAChR hits (pKi <4.5), exemplifying that subtle struc-
tural differences between compounds can have a signiﬁcant effect
on their selectivity proﬁles for homologous binding sites.
In conclusion, using a novel a7/Ls-AChBP chimeric protein crys-
tal structure we have successfully identiﬁed novel a7 receptor li-
gands that may serve as chemical starting points for further
optimization. In addition, the obtained results show that the novel
a7/Ls-AChBP structure provides an added value when applied in
structure-based virtual screening exercises that aim to identify no-
vel ligands for the a7 nAChR.
4. Experimental section
4.1. Materials
All cell culture reagents were obtained from Gibco (Invitrogen
Ltd, Paisley, UK), except fetal calf serum which was from Labtech
International (Ringmer, UK). The chimeric a7/5-HT3A receptor is
described by Bertrand and coworkers and was cloned into
pcDNA3.1 (Invitrogen, Paisley, UK) for expression in Human
embryonic kidney cells (HEK293).21 [3H]epibatidine (55.8 Ci/
mmol) was obtained from PerkinElmer Life Sciences (Cambridge,
UK).
4.2. Proprietary and commercial compound collections
A proprietary compound library containing 5315 structurally
diverse and drug-like compounds was used in our in silico screen-
ing procedure. The World Diversity Set was obtained from Specs
(www.specs.net, October 2011) as SD ﬁles. This database contains
chemically diverse screening compounds.
4.3. Database preparation
The compound libraries were converted into three-dimensional
structures using the MOE software package (version 2010.10,
Chemical Computing Group, Montreal, Canada). Counter ions and
solvent molecules were ﬁltered out, strong acids were deproto-nated and strong bases were protonated, atoms were assigned with
formal charges and ligands with cationic centers were selected.
Subsequently, conformations of the cationic ligands were gener-
ated using a systematic search method in MOE that was adjusted
for large chemical databases (conformation import function) using
the default settings. No ﬁlters were set and default constraints
were applied to the ligand conformation generation procedure to
yield a broad range of conformations and stereoisomers. Partial
atomic charges were calculated and the molecules were energy-
minimized according to a steepest-descent protocol using the
MMFF94x force ﬁeld in MOE.
4.4. Pharmacophore screening
A pharmacophore screen was applied to the conformations of
the cationic ligands to identify all compounds that were able to
ﬁt inside the binding pocket of the chimeric a7/Ls-AChBP protein
and form cation–p interactions with W145 at the same time. To
this end, the crystal structure of the chimeric a7/Ls-AChBP protein
in complex with the agonist epibatidine (PDB: 3SQ6; subunits A
and B) was used to construct a pharmacophore query. All heavy
atoms of the residues within 7.0 Å of epibatidine were selected
and used to construct an excluded volume that represents the
boundaries of the binding site. We chose an atom radius of 0.8 Å
for all heavy atoms. This is smaller than the atomic radius of car-
bon, to represent a bigger binding pocket which accounts for in-
duced-ﬁt effects upon ligand binding. The cationic center was
deﬁned at the position of the basic nitrogen atom of epibatidine
(located at 7-azabicyclo[2.2.1]heptane moiety) with a radius of
2.5 Å. All ligands that fulﬁlled the requirements of this pharmaco-
phore query were selected and subsequently their stereoisomers
were generated using the chiral_enumeration SVL script of MOE.
The compounds were saved as a multi-mol2 ﬁle.
4.5. Template preparation
The crystal structure of the chimeric a7/Ls-AChBP protein in
complex with the agonist epibatidine (PDB: 3SQ6; 2.8 Å) was used
in the docking procedure. The protein model was prepared using
the adjacent subunits A and B. All ligand and water molecules were
removed and hydrogen atoms were added using MOE. Partial
atomic charges (AMBER99) were calculated and a steepest-descent
energy-minimization was performed using the AMBER99 force
ﬁeld while keeping the heavy atoms ﬁxed. The minimized protein
structure was saved as a mol2-ﬁle.
Figure 7. Binding poses of compounds 4 (pose 1: A, B; pose 2: C, D) and 29 (E, F) obtained after docking studies into the chimeric a7/Ls-AChBP protein crystal structure.
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All selected ligands (including their stereoisomers) were docked
into the orthosteric binding pocket of the chimeric a7/Ls-AChBP
protein (PDB: 3SQ6) using the GOLD Suite software package
(version 5.1, CCDC, Cambridge, UK) with the ChemScore scoring
function and default settings, as described previously.16 The library
screening settings were selected and the pocket for docking was
assigned to be within 10 Å of the aromatic nitrogen atom (NE1)
of W145. For ligands, all ring corners were allowed to ﬂip just asthe planar and pyramidal nitrogen atoms. For each ligand the three
highest ranked poses were retained and the database was ranked
according to the scores. Since cation–p interactions are extremely
important in ligand–protein interactions with the nAChRs and
AChBPs,15,16 we determined the distance between the approximate
centroid of the W145 aromatic ring (atom CD2) and the cationic
nitrogen atom of the ligand using the GOLD Suite package. The
top-ranked compounds with poses that enable cation–p interac-
tions (distance ligand cationic nitrogen to W145 centroid <5.5 Å),
were visually inspected to verify optimal ligand–protein
6002 A. Akdemir et al. / Bioorg. Med. Chem. 20 (2012) 5992–6002interactions. A diverse, structurally novel and high-ranked subset
of ligands that are capable of forming cation–p interactions was se-
lected for displacement studies on the human a7 receptor. The
purity of all 10 experimentally validated hits was veriﬁed by liquid
chromatography–mass spectroscopy (LC–MS). All hits had a purity
of 96% or higher (see Supplementary data Table 2).
4.7. ECFP-4 2D similarity search
Two dimensional similarity searches were carried out using the
ECFP-4 (extended connectivity ﬁngerprints22) descriptor available
in Pipeline Pilot (version 6.1.5; Accelrys, San Diego, CA). All 38 se-
lected ligands were compared to known nicotinic receptor and a7
receptor ligands from the ChEMBL database (218 compounds;
molecular weight below 500 and Ki or EC50 10 lM). Only the
score and structure of the most similar known ligand is reported
for each of the selected compounds (Table 1).
4.8. Cell culture
HEK293 cells were maintained on 90 mm tissue culture plates
at 37 C and 7% CO2 in a humidiﬁed atmosphere. They were cul-
tured in DMEM:F12 with GlutaMAX™ I media (Dulbecco’s Modi-
ﬁed Eagle’s Medium/Nutrient Mix F12 (1:1), Invitrogen, Paisley,
UK) containing 10% fetal calf serum. For radioligand binding stud-
ies cells in 90 mm dishes were transfected using polyethyleneim-
ine (PEI, 25 kDa, linear powder, Polysciences Inc, Philadelphia,
USA). 30 ll PEI (1 mg/ml), 5 ll cDNA and 1 ml DMEM were incu-
bated for 10 min at room temperature, added drop wise to a 70–
80% conﬂuent plate, and incubated for 2–3 days before harvesting.
4.9. Radioligand binding assay on chimeric a7/5-HT3A receptor
Transfected HEK293 cells were harvested into 1 ml of ice-cold
HEPES buffer (10 mM, pH 7.4) and frozen. After thawing, they were
washed with HEPES buffer, resuspended, and 50 lg of cell mem-
branes incubated in 0.5 ml HEPES buffer containing 3 nM [3H]epi-
batidine. Non-speciﬁc binding was determined using 3 mM /
nicotine. For competition binding (10-point) reactions were incu-
bated for at least 2 h at 4 C. Reactions were terminated by vacuum
ﬁltration using a Brandel cell harvester onto GF/B ﬁlters pre-soaked
in 0.3% polyethyleneimine. Radioactivity was determined by scin-
tillation counting using a Beckman BCLS6500 (Fullerton, California,
USA). Individual competition binding experiments were analyzed
by iterative curve ﬁtting using the following equation in Prism
(version 4.03, GraphPad Software, Inc., San Diego, CA):
y ¼ Bmin þ Bmax  Bmin
1þ 10½LlogIC50
where Bmin is the non-speciﬁc binding, Bmax is the maximum
speciﬁc binding, [L] is the concentration of competing ligand and
IC50 is the concentration of competing ligand that blocks half of
the speciﬁc bound radioligand. Values are shown for a series of
experiments (n 3) and presented as the mean ± S.E.M.Acknowledgments
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